Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyzine SCHEMBL3061159 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL4491 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL4492 | 1.00 | DRD3 (1.00) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41450 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL491323 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL28290521 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL41448 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Etodroxizine SCHEMBL9064076 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Etodroxizine SCHEMBL668191 | 0.99 | DRD3 (0.98) | DRD3HRH1KCNH2CYP2D6USP2 | |
| Hydroxyzine SCHEMBL15532242 | 0.98 | DRD3 (0.95) | DRD3HRH1KCNH2CYP2D6USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024206825-A2 | MODIFIED ISCB NUCLEASES, MODIFIED GUIDE RNAS, AND USES THEREOF | Aera Therapeutics, Inc. (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2006118553-A1 | COMPOSITIONS COMPRISING NATURAL AGENTS FOR THE TREATMENT OF HIV-ASSOCIATED OPPORTUNISTIC INFECTIONS AND COMPLICATIONS AND METHODS FOR PREPARING AND USING COMPOSITIONS COMPRISING NATURAL AGENTS | WUTOH ANTHONY K (US) | 2006-11-09 | — | — | WO | claimed |
| US-20050266105-A1 | Compositions comprising natural agents for the treatment of HIV-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents | ASHIAGBOR KWAME T | 2005-12-01 | — | — | US | claimed |
| JP-63062069-A | — | — | None | — | — | JP | disclosed |
| EP-4706672-A9 | PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Pugong Biotech (Hangzhou) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-121157022-B | Control method and device for mechanical arm, robot, storage medium and program product | 北京极佳视界科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026086785-A1 | EUKARYOTIC CELLS EXPRESSING EXOGENOUS INOSINE MONOPHOSPHATE DEHYDROGENASE COMPRISING CHIMERIC ANTIGEN RECEPTOR BINDING TO GUCY2C | SHENZHEN WONDERCEL BIOTECHNOLOGY LIMITED (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-12583932-B2 | CD38 and ICAM1 antibodies and uses thereof | VIRTUOSO BINCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4706672-A1 | PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Pugong Biotech (Hangzhou) Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20260048111-A1 | Pharmaceutical Composition, Preparation Method and Use Thereof | PUGONG BIOTECH (HANGZHOU) CO., LTD. (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4218804-B1 | USE OF MYOSTATIN INHIBITORS AND COMBINATION THERAPIES | SCHOLAR ROCK INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-6768792-B2 | Identifying call parties to a call to an incoming calling party | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2004-07-27 | — | — | US | disclosed |
| US-20040092511-A1 | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders | BILLSTEIN STEPHAN ANTHONY (US) | 2004-05-13 | — | — | US | disclosed |
| US-20030112949-A1 | Fidentifying call parties to a call to an incoming calling party | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2003-06-19 | — | — | US | disclosed |
| EP-1109748-A4 | MULTISTAGE FACULTATIVE WASTEWATER TREATMENT SYSTEM | ATARA ENVIRONMENTAL INC (US) | 2001-09-05 | — | — | EP | disclosed |
| EP-1109748-A1 | MULTISTAGE FACULTATIVE WASTEWATER TREATMENT SYSTEM | Atara Environmental, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6086765-A | USING A CLOSED CYLINDRICAL VESSEL COMPRISING AN UPPERMOST AEROBIC ZONE, AN ANOXIC ZONE AND A LOWERMOST ANAEROBIC ZONE | ATARA ENVIRONMENTAL, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999061378-A1 | MULTISTAGE FACULTATIVE WASTEWATER TREATMENT SYSTEM | ATARA ENVIRONMENTAL, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5620961-A | PROTECTION AGAINST TISSUE DAMAGE | MARKOVIC NENAD S (US) | 1997-04-15 | — | — | US | disclosed |
| JP-S6362069-A | DOCUMENTATION DEVICE | MITSUBISHI ELECTRIC CORP | 1988-03-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266105-A1 | Compositions comprising natural agents for the treatment of HIV-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents | ZAP70, LSS, ITGAM | HRH1 4645/4885DRD3 4494/4885KCNH2 2466/4885 |
| US-20040092511-A1 | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders | MLNR, HTR3D, HTR1D | HRH1 223/4885DRD3 244/4885KCNH2 2858/4885 |
| US-20260048111-A1 | Pharmaceutical Composition, Preparation Method and Use Thereof | TLR5, CD47, LTA | HRH1 1697/4885DRD3 3905/4885KCNH2 4777/4885 |
| US-12583932-B2 | CD38 and ICAM1 antibodies and uses thereof | FCGR2A, FCGR3B, FCGR1A | HRH1 3137/4885DRD3 93/4885KCNH2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.